Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress 2023 EHA Congress 2023 ASCO Annual Meeting
Clinical Collections
Advances in Alzheimer’s

ACC 2024 Congress

Catch up on all the top stories and latest evidence in cardiology research with our ACC 2024 Congress hub page.
ADVANCED SEARCH
Log in
Top
International Journal of Clinical Oncology
Published in: International Journal of Clinical Oncology 2/2016

01-04-2016 | Original Article

Is scintigraphy necessary to detect migration of 125I seeds after brachytherapy for early prostate cancer?

Authors: Yu Odagaki, Makoto Ohori, Mana Yoshimura, Jun Nakshima, Yoshio Ohno, Ryuji Mikami, Hidetsugu Nakayama, Koichi Tokuuye, Masaaki Tachibana

Published in: International Journal of Clinical Oncology | Issue 2/2016

Login to get access

Abstract

Background

We investigated whether scintigraphy was superior to radiography for detecting migrated seeds after brachytherapy for prostate cancer.

Methods

We studied 57 patients with early prostate cancer who were treated with free 125I transperineal brachytherapy. Scintigraphy was used to detect seed migration on postoperative day (POD) 1, radiography was used on POD 2, and both tests were used on POD 30.

Results

The total number of implanted seeds in this study was 3,753 in 57 patients. Overall, there were 19 seed migrations in 12 patients. On POD 1, there were 4 seed migrations in 4 patients that were detected by scintigraphy. On POD 2, there were 10 seed migrations in 9 patients that were detected by radiography. On POD 30, 17 seed migrations were detected in 10 patients by radiography and 18 seeds migrations were detected by scintigraphy. However, 1 seed migration which was located outside of the detectable range of radiography was detected only by scintigraphy.

Conclusions

Both scintigraphy and radiography have similar abilities to detect migrated seeds 1 month after 125I brachytherapy for prostate cancer. While both tests have advantages and disadvantages, it is reasonable to only use radiography if scintigraphy is not available.
Literature
1.
Sugawara A, Nakashima J, Kunieda E et al (2011) Incidence of seed migration to the chest, abdomen, and pelvis after transperineal interstitial prostate brachytherapy with loose (125)I seeds. Radiat Oncol 6:130CrossRefPubMedPubMedCentral
2.
Older RA, Synder B, Krupski TL et al (2001) Radioactive implant migration in patients treated for localized prostate cancer with interstitial brachytherapy. J Urol 165:1590–1592CrossRefPubMed
3.
Tapen EM, Blasko JC, Grimm PD et al (1998) Reduction of radioactive seed embolization to the lung following prostate brachytherapy. Int J Radiat Oncol Biol Phys 42:1063–1067CrossRefPubMed
4.
Kono Y, Kubota K, Mitsumoto T et al (2008) Scintigraphic detection of 125I seeds after permanent brachytherapy for prostate cancer. J Nucl Med 49:541–545CrossRefPubMed
5.
Nguyen BD (2006) Cardiac and hepatic seed implant embolization after prostate brachytherapy. Urology 68(673):e17–e19PubMed
6.
Zhu AX, Walner KE, Frivold GP et al (2006) Prostate brachytherapy seed migration to the right coronary artery associated with an acute myocardial infarction. Brachytherapy 5:262–265CrossRefPubMed
7.
Nakano M, Uno H, Gotoh T et al (2006) Migration of prostate brachytherapy seeds to the vertebral venous plexus. Brachytherapy 5:127–130CrossRefPubMed
8.
Nguyen BD, Schild SE, Wong WW et al (2009) Prostate brachytherapy seed embolization to the right renal artery. Brachytherapy 8:309–312CrossRefPubMed
9.
Sugawara A, Kunieda E, Nakashima J et al (2010) Planar scintigraphy does not always detect migrated seeds after transperineal interstitial permanent prostate brachytherapy with 125I radioactive seeds. Internet J Urol 8:10
10.
Mandell L, Nori D, Anderson L et al (1985) The effects of permanent I-125 interstitial implantation on cortical bone. Int J Radiat Oncol Biol Phys 11:1029–1034CrossRefPubMed
11.
Huang DY, Schell MC, Weaver KA et al (1990) Dose distribution of 125I sources in different tissues. Med Phys 17:826–832CrossRefPubMed
12.
Merrick GS, Butler WM, Dorsey AT et al (2000) Seed fixity in the prostate/periprostatic region following brachtherapy. Int J Radiat Oncol Biol Phys 46:215–220CrossRefPubMed
13.
Reed DR, Wallner KE, Merrick GS et al (2007) A prospective randomized comparison of stranded versus loose 125I seeds for prostate brachytherapy. Brachytherapy 6:129–134CrossRefPubMed
14.
Battermann JJ (2000) I-125 implantation for localized prostate cancer: the Utrecht University experience. Radiother Oncol 57:269–272CrossRefPubMed
15.
Lee WR, deGuzman AF, Tomlinson SK et al (2002) Radioactive sources embedded in suture are associated with improved postimplant dosimetry in men treated with prostate brachytherapy. Radiother Oncol 65:123–127CrossRefPubMed
16.
Gao M, Wang JZ, Nag S et al (2007) Effects of seed migration on post-implant dosimetry of prostate brachytherapy. Med Phys 34:471–480CrossRefPubMed
17.
Fagundes HM, Keys RJ, Wojcik MF et al (2004) Transperineal TRUS-guided prostate brachytherapy using loose seeds versus RAPIDStrand: a dosimetric analysis. Brachytherapy 3:136–140CrossRefPubMed
18.
Heysek RV, Gwede CK, Torres-Roca J et al (2006) A dosimetric analysis of unstranded seeds versus customized stranded seeds in transperineal interstitial permanent prostate seed brachytherapy. Brachytherapy 5:244–250CrossRefPubMed
Metadata
Title
Is scintigraphy necessary to detect migration of 125I seeds after brachytherapy for early prostate cancer?
Authors
Yu Odagaki
Makoto Ohori
Mana Yoshimura
Jun Nakshima
Yoshio Ohno
Ryuji Mikami
Hidetsugu Nakayama
Koichi Tokuuye
Masaaki Tachibana
Publication date
01-04-2016
Publisher
Springer Japan
Published in
International Journal of Clinical Oncology / Issue 2/2016
Print ISSN: 1341-9625
Electronic ISSN: 1437-7772
DOI
https://doi.org/10.1007/s10147-015-0901-9

Other articles of this Issue 2/2016

International Journal of Clinical Oncology 2/2016 Go to the issue

Original Article

Relationship between quality of life instruments and phonatory function in tracheoesophageal speech with voice prosthesis

Invited Review Article

Clinical trials of antiangiogenic therapy for hepatocellular carcinoma

Original Article

Accuracy of preoperative diagnosis of lymph node metastasis for thoracic esophageal cancer patients from JCOG9907 trial

Original Article

Sarcopenia, but not visceral fat amount, is a risk factor of postoperative complications after major hepatectomy

Original Article

Current status of local treatment for early rectal cancer in Japan: a questionnaire survey by the 81st Congress of the Japanese Society for Cancer of the Colon and Rectum (JSCCR) in 2014

Original Article

Increased risk of certain second primary malignancies in patients treated for well-differentiated thyroid cancer
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine
Image Credits